BioVie Inc. announced on October 15, 2024, that it received a Notice of Allowance from the Japan Patent Office for its patent application covering novel liquid formulations of terlipressin. This allowance is expected to lead to the issuance of a Japanese patent within two to three weeks.
The allowed claims specifically cover a liquid formulation of terlipressin acetate that maintains stability at room temperature for up to 24 months and can be packaged in a pre-filled syringe. This formulation offers a significant advantage for treating patients with cirrhosis and ascites, especially in home-care settings.
This patent strengthens the intellectual property protection for BioVie's BIV201 program, adding to existing patents in the United States, India, and Chile, with eight additional markets pending. The innovation aims to provide a more patient-centric ambulatory treatment regimen.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.